Nivalis Therapeutics, Inc.'s Exec Vice President and CMO was just granted 100,000 options

David Malcom Rodman, Nivalis Therapeutics, Inc.'s Exec Vice President and CMO, just received 100,000 options from the company. The strike price of the options received was $7.77, and these expire on September 12, 2026. Rodman now owns at least 100,000 options on the company.

Some additional info was provided as follows:

The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. The options vest and become exercisable over a four-year period, with 25% vesting on the first anniversary of the grant date (September 12, 2017) and 1/48th of the options vesting monthly thereafter.

The above information was disclosed in a filing to the SEC. To see the filing, cli ck here.

To receive a free e-mail notification whenever Nivalis Therapeutics, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Securities to be offered to employees in employee benefit plans - June 21, 2018
Departure of Directors or Certain - June 14, 2018
Nivalis Therapeutics, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - June 11, 2018
Entry into a Material Definitive - June 11, 2018

Auto Refresh

Feedback